Life Science Nation Newsletter  | January 12,  2017  |  Issue 196

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Jan. 5  - Jan. 11)
Raises New Fund for Clinical-Stage Biotech, Medical Devices and Diagnostics
Looks Globally for Early Stage Therapeutic Opportunities
Invests Strategically in Healthcare IT
Invests in Software-Driven Devices, Diagnostics and Healthcare Services
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

LSN Book

LSN Videos
By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

The third RESI San Francisco Conference event, held on January 10th, saw 30 Innovation Challenge finalists competing for the votes of the largest RESI crowd to date. With 1,000 attendees present, more votes were cast than in any Innovation Challenge to date. Biotech, medical device, diagnostic and digital health companies all competed in the exhibition-style challenge for the top prize. Selected from over 100 applicants, the 30 finalists included many phenomenal startups. Here, LSN would like to present the 3 winners.

First Place: Pathcore (Toronto, Canada)

Second Place: Myndblue (Cambridge, MA)

Third Place: Propep Surgical (Austin, TX)
Thank you to all who competed in the RESI San Francisco Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.